What Glycinum Ozon Treats: Main Uses and Benefits

The therapeutic application of Glycinum Ozon is centered on supporting multiple physiological systems, often where symptoms are related to neurological imbalance or heightened physiological stress. The preparation may be relevant across several therapeutic domains involving supportive care.

Glycinum Ozon is generally relevant for individuals experiencing impaired sleep quality, is used for managing symptoms related to systemic imbalance (such as blood glucose and lipids), and is applied in addressing cognitive deficits or structural decline like joint discomfort. This preparation helps address symptom clusters that may become intense or disruptive, especially during phases when symptoms become more noticeable.

It is commonly used to help with groups of symptoms that may lead to subsequent daytime sleepiness and poor mental clarity.

This supportive benefit helps address symptoms of increased neurological or muscular activity and contributes to easing the overall symptom load during periods of increased distress. It is applicable in contexts marked by increased discomfort or tension and may assist with maintaining functional stability.

---

Quick Fact: Support for Symptoms of Sleep Disruption

Glycinum Ozon may assist with managing symptoms like difficulty falling asleep and non-restorative rest, which are often linked to noticeable daytime fatigue.

Official Eligibility and Non-Eligibility Status

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), do not authorize medical ozone therapy (associated with Glycinum Ozon) for therapeutic use, classifying ozone as a toxic gas with “no known useful medical application.” This status renders all populations ineligible for use in medical conditions where safety and effectiveness have not been proven.

Contraindicated Populations (Must Not Use)	Eligibility-Related Condition Exclusions
Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency (Favism)	Severe disorders of blood coagulation or active bleeding
Patients with uncontrolled Hyperthyroidism	Acute myocardial infarction
Women who are pregnant	Individual intolerance or known allergy to ozone

Age-Related Eligibility: Efficacy and safety are not established for any specific age group (pediatric, adolescent, adult, or older adult) due to the therapy's overall unapproved status for medical use in major jurisdictions.

Key Regulatory Constraint: The inhalation route of administration is explicitly prohibited due to the high toxicity of ozone gas to the respiratory system. Any device generating ozone for medical use is prohibited if it exceeds 0.05 parts per million in the air.

Interactions with other medicines and products

Official regulatory documentation for the active ingredient, Glycine (Aminoacetic acid), focuses on interaction risks related to its systemic metabolism and physiological effects, rather than standard pharmacokinetic interactions (e.g., CYP enzymes). The interaction profile is defined by specific restrictions and population-dependent considerations, largely drawn from official government prescribing information for high-dose systemic administration.

---

Documented Interaction Patterns

Interaction Type	Interacting Substance/Condition	Official Regulatory Statement
Contraindicated Condition	Anuria (Absence of urine output)	Use is formally contraindicated due to risks associated with fluid and solute retention.
Pharmacodynamic Risk	Digitalis (or related cardiac glycosides)	Exposure may lead to an increased risk of Digitalis Toxicity due to profound fluid and electrolyte shifts.
Metabolic-Dependent Risk	Impaired Liver Function	Risk of Hyperammonemia (ammonia accumulation) is noted due to the body's altered capacity to metabolize the active ingredient.

---

General Interaction Constraints

Systemic absorption of Glycine is associated with significant fluid and electrolyte shifts (such as Hyponatremia), which may impact the therapeutic effect or safety of co-administered agents sensitive to changes in water and salt balance. The official regulatory structure defines clear limitations on use based on a patient's underlying renal, hepatic, and cardiovascular status.

How Glycinum Ozon Works

The active component, Glycine, exerts its effects through a dual mechanistic profile: directly modulating central nervous system signaling and providing essential metabolic substrate supply. The mechanism is entirely attributed to the biological properties of Glycine as a neurotransmitter and metabolic precursor.

---

Modulating Neural Activity via Chloride Ion Influx

Glycine acts as a primary agonist for the Glycine Receptor ( GlyR), an inhibitory ion channel predominantly found in the spinal cord and brainstem. When Glycine binds, the GlyR opens, allowing Chloride ions ( Cl^-) to flow into the neuron, which hyperpolarizes the cell membrane. This Cl^- influx reduces the neuron's ability to fire, regulating overall neuronal excitability. This mechanism is relevant when targeted pathway adjustment is required to establish a stabilized physiological state within motor and sensory circuits.

---

️ Supporting Cellular Defense and Redox Regulation

In its metabolic capacity, Glycine functions as an essential rate-limiting precursor necessary for the body's synthesis of Glutathione (GSH), the major intrinsic antioxidant molecule. Glycine is incorporated by the enzyme Glutathione Synthetase, influencing adequate cellular levels of GSH. This mechanism influences metabolic function by enhancing the systemic redox buffer capacity, which contributes to the integrity of cellular structures.

The administration of Glycinum Ozon, which is formally standardized as a 1.5% Glycine Solution, is defined by its use as a sterile irrigating fluid strictly within a specialized clinical setting. The official route of administration is irrigation performed by transurethral instillation using appropriate surgical instrumentation. This pharmaceutical solution is designated as Not for Injection and is not intended for systemic, oral, or intravenous use.

Official Administration and Dosage

The volume of Glycine Solution administered is not based on a standardized daily dose or fixed maintenance range. Instead, the total amount used is determined solely at the discretion of the surgeon and is administered as required for irrigation during the acute procedure. This defines the product as a single-use application, and any unused portion of the solution must be discarded immediately after the surgical event.

Preparation and Procedural Constraints

Proper administration requires adherence to specific handling instructions. The solution must be prepared and used with aseptic technique. While the solution may be warmed to near body temperature, standard specifications indicate that certain temperature limits must not be exceeded. A key procedural constraint involves limiting the container elevation to no more than approximately 60 cm (24 inches) above the patient. This restriction minimizes the potential for excessive fluid absorption, a documented requirement for proper use. The administration schedule is acute and non-cyclic, focused entirely on the duration of the surgical intervention.

Research Evidence / Overview of Studies

Clinical research regarding formulations involving both Glycine and Ozone typically falls under the broader study of Ozone therapy and the metabolic role of the amino acid Glycine.

Efficacy in Targeted Outcome Measures

Studies have evaluated whether the use of Glycine-based ozone treatments is associated with changes in specific health indicators, often focusing on pain and inflammation in chronic conditions.

Research has explored whether the administration of ozone-related products in trials involving participants with joint issues, such as knee conditions, was associated with a change in pain scores and functional status measures. Comparative trials often assess outcomes against placebo or conventional therapeutic approaches.

Several studies reported specific outcome measures, with some showing an association between the intervention and reported changes in pain and disability metrics. However, large-scale, long-term, randomized controlled trial data remains necessary to establish conclusive findings for many potential uses.

Safety and Tolerability Profile

Clinical trials record adverse events and patient discontinuation rates related to the studied interventions.

• Commonly Reported Findings: The most commonly reported events across relevant trials have generally included transient localized discomfort or mild systemic effects.
• Serious Adverse Events: A small percentage of participants in intervention groups have reported serious adverse events (SAEs). The total rate of SAEs is low, and a causal link to the treatment is not established in every reported instance.

Trial data emphasize that individual risk factors and variations in response should be carefully considered, as study populations may not fully represent all patient demographics. The body of research underscores the necessity of clinical supervision for all therapeutic decisions.

Key Studies & References

1. Oxygen-Ozone Therapy for Reducing Pro-Inflammatory Cytokines Serum Levels in Musculoskeletal and Temporomandibular Disorders: A Comprehensive Review

Common questions about Glycinum Ozon (FAQ)

Q: How is Glycinum Ozon administered?

Official documentation indicates that this solution is administered using appropriate transurethral urologic instrumentation. It is strictly for surgical irrigation purposes. The product is not intended for injection using standard routes, such as intravenous or intramuscular injection.

Q: What class of drug is Glycinum Ozon?

Regulatory documents classify Glycine 1.5% Irrigation, USP, as a nonelectrolyte irrigating fluid. This means it is a specialized fluid indicated for use during transurethral surgical procedures.

Q: Are there any dietary or food interactions I should know about?

Official regulatory information focuses primarily on risks associated with drug-to-drug interactions (such as with Digitalis) and general warnings about fluid and electrolyte changes due to systemic absorption. Official product information does not consistently document specific food or dietary interactions for this solution.

Q: What is the FDA's regulatory status on this product?

The product, 1.5% Glycine Irrigation, USP, is recognized under official guidelines as a prescription-only drug. It is formally indicated for use as an irrigating fluid during transurethral surgical procedures.

Q: What should I do if I miss a dose?

This product is designed for use as a single application during an acute surgical event. It is administered as required for irrigation during the procedure. As it is used only during an acute surgical intervention, the concept of a 'missed dose' is not applicable.

Q: What other brand names contain Glycine Solution?

In addition to the generic name, Glycine 1.5% Irrigation, USP, the solution may be distributed under various brand names, such as TITAN XL, depending on the manufacturer and vendor. These products share the same active ingredient and concentration for urologic irrigation.

Q: Can I drink the solution?

Official documentation states that this solution is not for oral ingestion. The official labeling explicitly designates it as Not For Injection. It is indicated for urologic irrigation in a surgical setting and is not intended for oral, intravenous, or any other systemic use.

Q: What does the "Ozon" part of the name mean?

Official context suggests that the inclusion of 'Ozon' is likely a reference to the manufacturer. Products named 'Glycine Ozon' in some international markets are manufactured by a company named OZON LLC, indicating the term is a brand identifier rather than an active pharmaceutical ingredient.

How to Store and Dispose of Glycinum Ozon

The storage and disposal requirements for Glycinum Ozon (Glycine 1.5% Irrigation Solution) are strictly defined by regulatory labeling to maintain the product's integrity and sterility.

---

Storage Conditions

Storage Requirement	Official Condition
Temperature	Store at 20°C to 25°C (Controlled Room Temperature).
Protection	Must be protected from freezing and avoid excessive heat.
Container Integrity	The solution must be visually inspected; do not use if not clear or if the seal/overwrap is damaged.
Child Safety	Keep the product out of the sight and reach of children.

---

Handling and Disposal

As the product is a single-dose solution with no preservative, the contents of an opened container must be used promptly.

Unused portions must be discarded immediately. All disposal of the unused product or waste material must be carried out in line with local regulations.